Neuromodulatory Effects of Guanine-Based Purines in Health and Disease
- PMID: 30459558
- PMCID: PMC6232889
- DOI: 10.3389/fncel.2018.00376
Neuromodulatory Effects of Guanine-Based Purines in Health and Disease
Abstract
The function of guanine-based purines (GBPs) is mostly attributed to the intracellular modulation of heteromeric and monomeric G proteins. However, extracellular effects of guanine derivatives have also been recognized. Thus, in the central nervous system (CNS), a guanine-based purinergic system that exerts neuromodulator effects, has been postulated. The thesis that GBPs are neuromodulators emerged from in vivo and in vitro studies, in which neurotrophic and neuroprotective effects of these kinds of molecules (i.e., guanosine) were demonstrated. GBPs induce several important biological effects in rodent models and have been shown to reduce seizures and pain, stabilize mood disorder behavior and protect against gliomas and diseases related with aging, such as ischemia or Parkinson and Alzheimer diseases. In vitro studies to evaluate the protective and trophic effects of guanosine, and of the nitrogenous base guanine, have been fundamental for understanding the mechanisms of action of GBPs, as well as the signaling pathways involved in their biological roles. Conversely, although selective binding sites for guanosine have been identified in the rat brain, GBP receptors have not been still described. In addition, GBP neuromodulation may depend on the capacity of GBPs to interact with well-known membrane proteins in glutamatergic and adenosinergic systems. Overall, in this review article, we present up-to-date GBP biology, focusing mainly on the mechanisms of action that may lead to the neuromodulator role of GBPs observed in neurological disorders.
Keywords: Alzheimer’s disease; Parkinson’s disease; glutamatergic system; guanosine; neuromodulation; purinergic system.
Figures


Similar articles
-
Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders.Aging Dis. 2016 Oct 1;7(5):657-679. doi: 10.14336/AD.2016.0208. eCollection 2016 Oct. Aging Dis. 2016. PMID: 27699087 Free PMC article. Review.
-
The Guanine-Based Purinergic System: The Tale of An Orphan Neuromodulation.Front Pharmacol. 2016 Jun 17;7:158. doi: 10.3389/fphar.2016.00158. eCollection 2016. Front Pharmacol. 2016. PMID: 27378923 Free PMC article. Review.
-
Proposal of a guanine-based purinergic system in the mammalian central nervous system.Pharmacol Ther. 2007 Dec;116(3):401-16. doi: 10.1016/j.pharmthera.2007.07.004. Epub 2007 Aug 22. Pharmacol Ther. 2007. PMID: 17884172 Review.
-
Trophic effects of purines in neurons and glial cells.Prog Neurobiol. 1999 Dec;59(6):663-90. doi: 10.1016/s0301-0082(99)00017-9. Prog Neurobiol. 1999. PMID: 10845757 Review.
-
Guanine based purines inhibit [(3)H]glutamate and [(3)H]AMPA binding at postsynaptic densities from cerebral cortex of rats.Brain Res. 2002 Feb 22;928(1-2):106-12. doi: 10.1016/s0006-8993(01)03368-6. Brain Res. 2002. PMID: 11844477
Cited by
-
Neuroinflammation and Neuromodulation in Neurological Diseases.Behav Sci (Basel). 2019 Sep 12;9(9):99. doi: 10.3390/bs9090099. Behav Sci (Basel). 2019. PMID: 31547441 Free PMC article.
-
Adenosine A1-A2A Receptor-Receptor Interaction: Contribution to Guanosine-Mediated Effects.Cells. 2019 Dec 13;8(12):1630. doi: 10.3390/cells8121630. Cells. 2019. PMID: 31847113 Free PMC article.
-
Raising the Guanosine-Based Molecules as Regulators of Excitable Tissues by the Exosomal-Vehiculated Signaling.Front Pharmacol. 2021 Jul 30;12:658370. doi: 10.3389/fphar.2021.658370. eCollection 2021. Front Pharmacol. 2021. PMID: 34393768 Free PMC article. No abstract available.
-
Effects of intranasal guanosine administration on brain function in a rat model of ischemic stroke.Purinergic Signal. 2021 Jun;17(2):255-271. doi: 10.1007/s11302-021-09766-x. Epub 2021 Apr 9. Purinergic Signal. 2021. PMID: 33834349 Free PMC article.
-
Guanosine and GMP increase the number of granular cerebellar neurons in culture: dependence on adenosine A2A and ionotropic glutamate receptors.Purinergic Signal. 2019 Dec;15(4):439-450. doi: 10.1007/s11302-019-09677-y. Epub 2019 Sep 2. Purinergic Signal. 2019. PMID: 31478180 Free PMC article.
References
-
- Baron B. M., Dudley M. W., McCarty D. R., Miller F. P., Reynolds I. J., Schmidt C. J. (1989). Guanine nucleotides are competitive inhibitors of N-methyl-D-aspartate at its receptor site both in vitro and in vivo. J. Pharmacol. Exp. Ther. 250, 162–169. - PubMed